Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines

Gene Copy-Number Alterations: A Cost-Benefit Analysis

(2013) Yun-Chi Tang et al.   CELL

DNA damage associated with mitosis and cytokinesis failure

(2013) M T Hayashi et al.   ONCOGENE

The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

(2012) Jayasree S. Nair et al.   CELL CYCLE

Aurora A kinase (AURKA) in normal and pathological cell division

(2012) Anna S. Nikonova et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Cell division control by the Chromosomal Passenger Complex

(2012) Maike S. van der Waal et al.   EXPERIMENTAL CELL RESEARCH

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

(2012) Gary K. Schwartz et al.   INVESTIGATIONAL NEW DRUGS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells

(2012) V. Sehdev et al.   MOLECULAR CANCER THERAPEUTICS

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

(2012) Robert C. Smallridge et al.   THYROID

Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein

(2011) Jean-Charles Gabillard et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT

(2011) Enke Baldini et al.   BMC CANCER

The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents

(2011) Deborah R. Wysong et al.   CELL CYCLE

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development

(2011) G. Fernandez-Miranda et al.   DEVELOPMENT

Gene expression profile of human thyroid cancer in relation to its mutational status

(2011) Dagmara Rusinek et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947

(2010) S. Libertini et al.   ENDOCRINE-RELATED CANCER

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications

(2008) Manuel T. Silva et al.   APOPTOSIS

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

(2008) Y. Arlot-Bonnemains et al.   ENDOCRINE-RELATED CANCER